The document summarizes a presentation on challenges facing healthcare systems and opportunities for innovation through bioconvergence. It discusses major challenges like rising costs and an aging population with more chronic diseases. This is driving interest in integrated care models and technologies that can help manage health more efficiently. The presentation promotes Switzerland's biocluster as a unique hub bringing together academic research and industry to drive medical innovation through cross-sector collaboration and translation of new technologies from labs to market.
This document discusses big data analytics in healthcare. It begins by defining translational bioinformatics and discussing the challenges and opportunities of big data. It then outlines how big data is generated from a variety of clinical, administrative, and other sources. Technologies like Hadoop and NoSQL databases are important for analyzing large and diverse healthcare datasets. The document argues that big data analytics can help innovate and accelerate healthcare by enabling predictive analytics, personalized medicine, and improving outcomes while reducing costs.
"The latest news from Flandres (Belgium)" CRC screeningLuc Colemont
This document summarizes the results of the 2014 Flemish screening program for colon cancer. It provides statistics on participation rates, number of people screened, positive screening results, and colonoscopies performed. The key findings are that 657,887 people were screened in 2014, with a 50.3% participation rate and 7.7% positive results. Approximately 2500 colon cancers and many polyps were found through the screening program colonoscopies. The screening program has been successful in reducing colorectal cancer cases and deaths.
The document discusses major challenges in healthcare such as rising costs and an aging population, and proposes that convergence across disciplines like biotechnology, medical technology, and information technology can help address these challenges by enabling more integrated and personalized care. It promotes the region of Campus Biotech in Switzerland as a hub for innovation through collaboration between academic and industry partners to develop new technologies and solutions in areas like molecular medicine, eHealth, and neuroengineering.
The document summarizes a keynote presentation on medical revolution and new technologies. It discusses:
1. The challenges facing healthcare including rising costs, aging populations, and chronic diseases.
2. Towards developing an integrated healthcare system with personalized, predictive, and preventative medicine using technologies like remote monitoring, big data analytics, and mobile health.
3. Innovation in areas like genomics, proteomics, bioconvergence, and interdisciplinary collaboration between fields like nanotechnology, materials science, and computing can help address these challenges.
GenSearch - Innovation in Healthcare: What is the Point?Alix Aubert
In this white paper, you will discover instances where innovation in technology and organisational operations are connecting patients to healthcare providers and are sharing secure clinical data with researchers. Others have disrupted traditional manufacturing methods to improve processes and some have even transformed organisational operations to create customer trust, value, and to improve outcomes for patients.
This document discusses the history and future of medical technology. It describes how medical technology has improved healthcare by enabling earlier diagnosis, less invasive treatments, and shorter hospital stays. The document provides a timeline of medical technologies over the last 200 years and how they have led to dramatic increases in life expectancy. Examples are given of current advanced technologies and future innovations, such as reducing the need for melanoma biopsies and creating needle-free methods for diabetes care. Both the pros and cons of medical technology are reviewed.
This document discusses big data analytics in healthcare. It begins by defining translational bioinformatics and discussing the challenges and opportunities of big data. It then outlines how big data is generated from a variety of clinical, administrative, and other sources. Technologies like Hadoop and NoSQL databases are important for analyzing large and diverse healthcare datasets. The document argues that big data analytics can help innovate and accelerate healthcare by enabling predictive analytics, personalized medicine, and improving outcomes while reducing costs.
"The latest news from Flandres (Belgium)" CRC screeningLuc Colemont
This document summarizes the results of the 2014 Flemish screening program for colon cancer. It provides statistics on participation rates, number of people screened, positive screening results, and colonoscopies performed. The key findings are that 657,887 people were screened in 2014, with a 50.3% participation rate and 7.7% positive results. Approximately 2500 colon cancers and many polyps were found through the screening program colonoscopies. The screening program has been successful in reducing colorectal cancer cases and deaths.
The document discusses major challenges in healthcare such as rising costs and an aging population, and proposes that convergence across disciplines like biotechnology, medical technology, and information technology can help address these challenges by enabling more integrated and personalized care. It promotes the region of Campus Biotech in Switzerland as a hub for innovation through collaboration between academic and industry partners to develop new technologies and solutions in areas like molecular medicine, eHealth, and neuroengineering.
The document summarizes a keynote presentation on medical revolution and new technologies. It discusses:
1. The challenges facing healthcare including rising costs, aging populations, and chronic diseases.
2. Towards developing an integrated healthcare system with personalized, predictive, and preventative medicine using technologies like remote monitoring, big data analytics, and mobile health.
3. Innovation in areas like genomics, proteomics, bioconvergence, and interdisciplinary collaboration between fields like nanotechnology, materials science, and computing can help address these challenges.
GenSearch - Innovation in Healthcare: What is the Point?Alix Aubert
In this white paper, you will discover instances where innovation in technology and organisational operations are connecting patients to healthcare providers and are sharing secure clinical data with researchers. Others have disrupted traditional manufacturing methods to improve processes and some have even transformed organisational operations to create customer trust, value, and to improve outcomes for patients.
This document discusses the history and future of medical technology. It describes how medical technology has improved healthcare by enabling earlier diagnosis, less invasive treatments, and shorter hospital stays. The document provides a timeline of medical technologies over the last 200 years and how they have led to dramatic increases in life expectancy. Examples are given of current advanced technologies and future innovations, such as reducing the need for melanoma biopsies and creating needle-free methods for diabetes care. Both the pros and cons of medical technology are reviewed.
This document provides a summary of key developments in cancer informatics in 2019. It recognizes individuals who have made important contributions to the field. It discusses how real-world data and single-cell measurements were major areas of focus. Challenges discussed include addressing biases, incentivizing data sharing, and improving diversity and inclusion. The growth of data science, precision oncology, and cloud computing are noted. Gender bias in single-cell analysis is addressed. Machine learning and data analytics are now mainstream in biomedical research.
Addressign the Need for a Paradigm Shift in Healthcareeuhealthfutures
This document summarizes a presentation on the future of European healthcare. It notes that current healthcare systems are unsustainable even in the medium term due to rising costs from an aging population and new technologies. However, there is significant resistance to change from stakeholders with vested interests in the status quo. The document suggests that disruptive innovation from outside the existing system may be needed to drive the transformative changes required to address these challenges in a sustainable way.
SMi Group's 3d Cell Culture 2019 conferenceDale Butler
This document provides information on the 3rd Annual Conference on 3D Cell Culture taking place on February 20-21, 2019 in London, UK.
The conference will feature presentations and panel discussions on developing 3D cell culture technologies and their applications in drug development and disease modeling. Speakers will discuss topics such as organ-on-chip technologies, 3D bioprinting, developing translationally relevant 3D models, and using organoids and 3D neuronal/retinal models for toxicity testing. A pre-conference workshop on February 19th will demonstrate a new technique for histological assessment of 3D spheroid arrays.
Reverse Innovation in Global Health and DevelopmentXynteo
Maurizio Vecchione represents Global Good to deliver the presentation on Reverse Innovation in Global Health and Global Development to drive catalytic invention, with the power to move the bottom Billion into the Sustainable Development Goals. Case studies include AI-based Microscopy, Photonic Fence for vector control in health and agriculture eradication, High Sensitivity Point of Care Diagnostics for disease eradication.
Reverse Innovation in Global Health and DevelopmentBrian Bragg
Maurizio Vecchione represents Global Good to deliver the presentation on Reverse Innovation in Global Health and Global Development to drive catalytic invention, with the power to move the bottom Billion into the Sustainable Development Goals. Case studies include AI-based Microscopy, Photonic Fence for vector control in health and agriculture eradication, High Sensitivity Point of Care Diagnostics for disease eradication.
Medical technology refers to the field of advancing medical practices through technology to diagnose, assess, and treat diseases. The document discusses the history of major medical technology milestones from the 13th century to present day. Recent advances discussed include augmented reality for medical education, improved cancer immunotherapies and diabetes management tools, and gene editing technology. While medical technology provides benefits like improved health outcomes and economic benefits, it also presents risks such as data privacy concerns and over-reliance on technology. Overall, medical technology has become increasingly popular and transformative to healthcare.
The document discusses five innovative health technologies that have been enabled by support from the Centre for Process Innovation. It describes technologies such as nanoparticles that can enhance radiotherapy treatment for cancer by generating free radicals without needing oxygen. It also discusses an automated device that can check if nasogastric tubes are correctly placed in patients' stomachs to eliminate human errors that have caused deaths. The document emphasizes how innovation centers help move research breakthroughs and ideas to commercialization to develop products that can improve health outcomes.
Transformative governance of personal health ecosystems Totti Könnölä
Invited speech of Dr. Totti Könnölä, CEO inf Insight Foresight Institute in the scientific conference 'Bioengineering for Healthy Ageing. Adding Life to Years' November 9th 2017, CosmoCaixa Barcelona.
Future personal health ecosystems encompass various areas of application such as chronic disease management, life-style management, independent living and emergency services. Such future systems assist in the provision of continuous, quality controlled and personalised health services to empowered individuals regardless of location and provide a horizontal development area across variety of patients, clinical specialties, technology fields and health services. Hence, the development of such ecosystems requires transformative governance that enable coordination and federation of diverse stakeholders.
This document discusses the convergence of life sciences and microelectronics for novel health solutions. It notes several trends driving demand for innovative health solutions, including rising healthcare costs, aging populations, and increased consumerism/digitization of health. Two key challenges are the differences between life sciences and technology in timelines, regulations, business models, and culture. However, smart players are adapting and collaborating across sectors to develop integrated solutions that can improve patient outcomes through tools like screening tests, diagnostics, monitoring, and wellness programs supported by data analytics. The document advocates for Flanders to develop a long-term vision of a life science and technology-driven network economy by building on collaborations between key clusters like FlandersBio and D
American Healthcare Industrial RevolutionRobert Bond
Breakthroughs in information technology, telecommunications, and medical science have set the stage for a dramatic transformation of healthcare. The realities of large numbers of aging, chronically ill people will spark a crisis that will galvanize public opinion and lead to rapid change. Here’s what you should know regarding challenges and opportunities in the new landscape.
Medical device companies are looking to emerging markets like India, China, Brazil and Russia for growth due to challenges in developed markets from the global financial crisis. The emerging markets offer major opportunities due to their growing economies, expanding middle class populations and increasing healthcare spending. However, to successfully launch devices in these markets, companies will need to understand the local market needs, create customized and affordable products for each market, develop new collaborative R&D networks to drive innovation, and partner with local players to better serve customers.
The document discusses the role and work of Professor Lord Darzi with the World Innovation Summit for Health (WISH). WISH aims to bring together global leaders to find innovative solutions to health challenges through collaboration. Lord Darzi believes radical innovation is needed to address issues like mental health and obesity. As Executive Chair of WISH, he hopes to make it a leading global forum for health like the Davos economic forum. Lord Darzi also discusses his career in minimally invasive and robotic surgery techniques and his views on improving patient care through more accessible and cost-effective models focused on chronic diseases.
Want to know about System Innovation? This blog will help you with system innovation and its journey of transformation.
To know more details, visit : https://mitidinnovation.com/recreation/introduction-to-system-innovation-a-journey-of-transformation/
The DayOne Conference 2019 was held on September 9th at FHNW in Muttenz. The one-day conference focused on shaping the future of health and included panels with patients and industry professionals, sessions on ethics, financing innovation, and a workshop. There were over 450 participants, including 30 projects/entrepreneurs, 40 volunteers, and a keynote from digital health futurist Maneesh Juneja. The conference was organized by the DayOne team and supported various partners to bring together over 1500 healthcare innovators in the Basel area.
Kim Solez Yukako Yagi Digital transplant pathology white paperKim Solez ,
This document discusses digital transplant pathology and proposes initial projects for a working group. It begins with background on digital pathology and its potential to address declining interest in pathology. Only 30 of over 1000 pathology departments worldwide were fully digitized in 2019. The document then discusses exponentially advancing technologies and influential figures in the field. It proposes that the working group focus on practical digital pathology examples and first projects related to transplant pathology. One such example discussed is automated fluorescence in situ hybridization (FISH) quantification from whole slide images using deep learning.
Technological advancements are impacting various areas like health, education, and the environment on a global scale. In health, examples mentioned include a blue-tooth enabled biosensor wristwatch that monitors vital signs, artificial limbs that can receive commands from the brain, an insulin nanopump, and research curing type 1 diabetes. In education, online games and augmented reality tools are being used, and emphasis is placed on non-linear global learning and early cultural exchanges. Emerging environmental technologies can make paper obsolete and harness energy from waves and waste conversion. Leadership will need to focus on initiatives, funding, and ethical and transformational approaches to maximize benefits and opportunities around futures technology.
Dear colleagues,
We are pleased to inform you that the third issue of our publication is ready and available for you to enjoy. We hope that our great enthusiasm and eagerness for a better knowledge of hysteroscopy, will make reading this journal arouse your interest in this fascinating field. Hysteroscopy Newsletter is an opened forum to all professionals who want to contribute with their knowledge and even share their doubts with a word-wide gynecological community.
SHARE & ENJOY IT !!!!!!
Healthcare-associated infections are a major public health problem worldwide and a leading cause of death in hospitals. Antimicrobial resistance poses a serious threat as many antibiotics are becoming ineffective. Disinfection and sanitization are important first lines of defense against disease-causing microbes. However, research and development of new and effective disinfectants has been limited by a lack of funding and public perception of disinfectants as non-essential. Increased investment in disinfectant research and ensuring proper use and training are needed to address the growing risks of antibiotic resistance.
This document discusses how open innovation can transform the healthcare and life sciences industry. It argues that the traditional linear model of operations for these industries needs to change given rising costs, failing drug pipelines, and demands for improved outcomes. Open innovation enables collaboration across organizations through knowledge sharing. The document outlines a three step technology-driven agenda for healthcare and life sciences companies to become more open and patient-centric: 1) Transitioning R&D from silos to open environments, 2) Shifting marketing from one-way to co-creative, and 3) Adopting predictive clinical diagnosis. Technology plays a key role by facilitating knowledge exchange, collaboration, and analytics across organizations.
Revolutionizing Healthcare The Biomedical Industry's Quest for InnovationAustin Seal
The document provides a comprehensive overview of the biomedical industry, examining its history, current challenges, and promising future developments. It traces the roots of biomedicine back to ancient civilizations and explores key milestones like the Renaissance period and modern discoveries of germ theory and antibiotics. Current challenges include navigating regulatory hurdles, addressing ethical dilemmas, and improving global healthcare access. Exciting areas of innovation discussed are precision medicine, regenerative medicine, artificial intelligence, 3D printing, and telemedicine. The future holds possibilities such as artificial organs and neurotechnology breakthroughs, though developing ethical frameworks and global collaboration will be important to ensure responsible progress.
This document provides a summary of key developments in cancer informatics in 2019. It recognizes individuals who have made important contributions to the field. It discusses how real-world data and single-cell measurements were major areas of focus. Challenges discussed include addressing biases, incentivizing data sharing, and improving diversity and inclusion. The growth of data science, precision oncology, and cloud computing are noted. Gender bias in single-cell analysis is addressed. Machine learning and data analytics are now mainstream in biomedical research.
Addressign the Need for a Paradigm Shift in Healthcareeuhealthfutures
This document summarizes a presentation on the future of European healthcare. It notes that current healthcare systems are unsustainable even in the medium term due to rising costs from an aging population and new technologies. However, there is significant resistance to change from stakeholders with vested interests in the status quo. The document suggests that disruptive innovation from outside the existing system may be needed to drive the transformative changes required to address these challenges in a sustainable way.
SMi Group's 3d Cell Culture 2019 conferenceDale Butler
This document provides information on the 3rd Annual Conference on 3D Cell Culture taking place on February 20-21, 2019 in London, UK.
The conference will feature presentations and panel discussions on developing 3D cell culture technologies and their applications in drug development and disease modeling. Speakers will discuss topics such as organ-on-chip technologies, 3D bioprinting, developing translationally relevant 3D models, and using organoids and 3D neuronal/retinal models for toxicity testing. A pre-conference workshop on February 19th will demonstrate a new technique for histological assessment of 3D spheroid arrays.
Reverse Innovation in Global Health and DevelopmentXynteo
Maurizio Vecchione represents Global Good to deliver the presentation on Reverse Innovation in Global Health and Global Development to drive catalytic invention, with the power to move the bottom Billion into the Sustainable Development Goals. Case studies include AI-based Microscopy, Photonic Fence for vector control in health and agriculture eradication, High Sensitivity Point of Care Diagnostics for disease eradication.
Reverse Innovation in Global Health and DevelopmentBrian Bragg
Maurizio Vecchione represents Global Good to deliver the presentation on Reverse Innovation in Global Health and Global Development to drive catalytic invention, with the power to move the bottom Billion into the Sustainable Development Goals. Case studies include AI-based Microscopy, Photonic Fence for vector control in health and agriculture eradication, High Sensitivity Point of Care Diagnostics for disease eradication.
Medical technology refers to the field of advancing medical practices through technology to diagnose, assess, and treat diseases. The document discusses the history of major medical technology milestones from the 13th century to present day. Recent advances discussed include augmented reality for medical education, improved cancer immunotherapies and diabetes management tools, and gene editing technology. While medical technology provides benefits like improved health outcomes and economic benefits, it also presents risks such as data privacy concerns and over-reliance on technology. Overall, medical technology has become increasingly popular and transformative to healthcare.
The document discusses five innovative health technologies that have been enabled by support from the Centre for Process Innovation. It describes technologies such as nanoparticles that can enhance radiotherapy treatment for cancer by generating free radicals without needing oxygen. It also discusses an automated device that can check if nasogastric tubes are correctly placed in patients' stomachs to eliminate human errors that have caused deaths. The document emphasizes how innovation centers help move research breakthroughs and ideas to commercialization to develop products that can improve health outcomes.
Transformative governance of personal health ecosystems Totti Könnölä
Invited speech of Dr. Totti Könnölä, CEO inf Insight Foresight Institute in the scientific conference 'Bioengineering for Healthy Ageing. Adding Life to Years' November 9th 2017, CosmoCaixa Barcelona.
Future personal health ecosystems encompass various areas of application such as chronic disease management, life-style management, independent living and emergency services. Such future systems assist in the provision of continuous, quality controlled and personalised health services to empowered individuals regardless of location and provide a horizontal development area across variety of patients, clinical specialties, technology fields and health services. Hence, the development of such ecosystems requires transformative governance that enable coordination and federation of diverse stakeholders.
This document discusses the convergence of life sciences and microelectronics for novel health solutions. It notes several trends driving demand for innovative health solutions, including rising healthcare costs, aging populations, and increased consumerism/digitization of health. Two key challenges are the differences between life sciences and technology in timelines, regulations, business models, and culture. However, smart players are adapting and collaborating across sectors to develop integrated solutions that can improve patient outcomes through tools like screening tests, diagnostics, monitoring, and wellness programs supported by data analytics. The document advocates for Flanders to develop a long-term vision of a life science and technology-driven network economy by building on collaborations between key clusters like FlandersBio and D
American Healthcare Industrial RevolutionRobert Bond
Breakthroughs in information technology, telecommunications, and medical science have set the stage for a dramatic transformation of healthcare. The realities of large numbers of aging, chronically ill people will spark a crisis that will galvanize public opinion and lead to rapid change. Here’s what you should know regarding challenges and opportunities in the new landscape.
Medical device companies are looking to emerging markets like India, China, Brazil and Russia for growth due to challenges in developed markets from the global financial crisis. The emerging markets offer major opportunities due to their growing economies, expanding middle class populations and increasing healthcare spending. However, to successfully launch devices in these markets, companies will need to understand the local market needs, create customized and affordable products for each market, develop new collaborative R&D networks to drive innovation, and partner with local players to better serve customers.
The document discusses the role and work of Professor Lord Darzi with the World Innovation Summit for Health (WISH). WISH aims to bring together global leaders to find innovative solutions to health challenges through collaboration. Lord Darzi believes radical innovation is needed to address issues like mental health and obesity. As Executive Chair of WISH, he hopes to make it a leading global forum for health like the Davos economic forum. Lord Darzi also discusses his career in minimally invasive and robotic surgery techniques and his views on improving patient care through more accessible and cost-effective models focused on chronic diseases.
Want to know about System Innovation? This blog will help you with system innovation and its journey of transformation.
To know more details, visit : https://mitidinnovation.com/recreation/introduction-to-system-innovation-a-journey-of-transformation/
The DayOne Conference 2019 was held on September 9th at FHNW in Muttenz. The one-day conference focused on shaping the future of health and included panels with patients and industry professionals, sessions on ethics, financing innovation, and a workshop. There were over 450 participants, including 30 projects/entrepreneurs, 40 volunteers, and a keynote from digital health futurist Maneesh Juneja. The conference was organized by the DayOne team and supported various partners to bring together over 1500 healthcare innovators in the Basel area.
Kim Solez Yukako Yagi Digital transplant pathology white paperKim Solez ,
This document discusses digital transplant pathology and proposes initial projects for a working group. It begins with background on digital pathology and its potential to address declining interest in pathology. Only 30 of over 1000 pathology departments worldwide were fully digitized in 2019. The document then discusses exponentially advancing technologies and influential figures in the field. It proposes that the working group focus on practical digital pathology examples and first projects related to transplant pathology. One such example discussed is automated fluorescence in situ hybridization (FISH) quantification from whole slide images using deep learning.
Technological advancements are impacting various areas like health, education, and the environment on a global scale. In health, examples mentioned include a blue-tooth enabled biosensor wristwatch that monitors vital signs, artificial limbs that can receive commands from the brain, an insulin nanopump, and research curing type 1 diabetes. In education, online games and augmented reality tools are being used, and emphasis is placed on non-linear global learning and early cultural exchanges. Emerging environmental technologies can make paper obsolete and harness energy from waves and waste conversion. Leadership will need to focus on initiatives, funding, and ethical and transformational approaches to maximize benefits and opportunities around futures technology.
Dear colleagues,
We are pleased to inform you that the third issue of our publication is ready and available for you to enjoy. We hope that our great enthusiasm and eagerness for a better knowledge of hysteroscopy, will make reading this journal arouse your interest in this fascinating field. Hysteroscopy Newsletter is an opened forum to all professionals who want to contribute with their knowledge and even share their doubts with a word-wide gynecological community.
SHARE & ENJOY IT !!!!!!
Healthcare-associated infections are a major public health problem worldwide and a leading cause of death in hospitals. Antimicrobial resistance poses a serious threat as many antibiotics are becoming ineffective. Disinfection and sanitization are important first lines of defense against disease-causing microbes. However, research and development of new and effective disinfectants has been limited by a lack of funding and public perception of disinfectants as non-essential. Increased investment in disinfectant research and ensuring proper use and training are needed to address the growing risks of antibiotic resistance.
This document discusses how open innovation can transform the healthcare and life sciences industry. It argues that the traditional linear model of operations for these industries needs to change given rising costs, failing drug pipelines, and demands for improved outcomes. Open innovation enables collaboration across organizations through knowledge sharing. The document outlines a three step technology-driven agenda for healthcare and life sciences companies to become more open and patient-centric: 1) Transitioning R&D from silos to open environments, 2) Shifting marketing from one-way to co-creative, and 3) Adopting predictive clinical diagnosis. Technology plays a key role by facilitating knowledge exchange, collaboration, and analytics across organizations.
Revolutionizing Healthcare The Biomedical Industry's Quest for InnovationAustin Seal
The document provides a comprehensive overview of the biomedical industry, examining its history, current challenges, and promising future developments. It traces the roots of biomedicine back to ancient civilizations and explores key milestones like the Renaissance period and modern discoveries of germ theory and antibiotics. Current challenges include navigating regulatory hurdles, addressing ethical dilemmas, and improving global healthcare access. Exciting areas of innovation discussed are precision medicine, regenerative medicine, artificial intelligence, 3D printing, and telemedicine. The future holds possibilities such as artificial organs and neurotechnology breakthroughs, though developing ethical frameworks and global collaboration will be important to ensure responsible progress.
Similar to Innovate for health csem 17.09.2014xxx (20)
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Debunking Nutrition Myths: Separating Fact from Fiction"AlexandraDiaz101
In a world overflowing with diet trends and conflicting nutrition advice, it’s easy to get lost in misinformation. This article cuts through the noise to debunk common nutrition myths that may be sabotaging your health goals. From the truth about carbohydrates and fats to the real effects of sugar and artificial sweeteners, we break down what science actually says. Equip yourself with knowledge to make informed decisions about your diet, and learn how to navigate the complexities of modern nutrition with confidence. Say goodbye to food confusion and hello to a healthier you!
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
2. HEALTH CARE
“Medical revolution and new technologies”
The challenges
Towards bioconvergence
Our contribution
Anticipate the Future
3. HEALTH CARE
“Medical revolution and new technologies”
The challenges
Towards bioconvergence
Our contribution
Anticipate the Future
4. Crossing Visions
19/09/14 | 4
MAJOR CHALLENGES
IN HEALTHCARE
Therapeutic challenges
Demographics
Cost
Access
Variation in clinical practice
Inefficient use of information
Fragmented care versus integrated care
Duplication, defensive medicine & waste
Protracted adoption of innovation
6. DEMOGRAPHICS:
WE LIVE
LONGER
2
Crossing Visions
19/09/14 | 6 Life Expectancy at Birth
CH: 84.7
1900 1950 2010 2050
Benchmark:
Life expectancy in imperial Rome was ~ 30 years
CH: 80.5
Age 60 – 2 Billion
Age 80 – 380 Million
Age 100 – 2 Million
8. Crossing Visions
19/09/14 | 8
THE BURDEN OF
CHRONIC DISEASES
Healthcare
spending for people
with chronic
conditions
Nearly half of us will have
chronic conditions
by 2030:
Diabetes
Neurodegenerative Disease
Obesity
Hypertension
Arthritis
Atherosclerosis
Stroke
Cancer
Degenerative Joint disease
Degenerative Spine Disease
Obstructive Lung Disease
Healthcare
spending for people
without chronic
conditions
Chronic conditions
account for 83%
of health care
4spending
10. Crossing Visions
19/09/14 | 10
TOWARD
HEALTHIER
LIFE
Past model
Healthy life
Present model
Healthy life
Compressed morbidity model
Disease
Disability
Disease
Disability
Healthy life DiseLaisfee years gained
Disability
11. Click to edit Master title style
MEDTECH
“Medical revolution and new technologies”
The challenges
Towards Bioconvergence
Our contribution
Anticipate the Future
11.6.2013 IBM Technology Day 2013, Keynote B. Dubuis 11
12. Crossing Visions
19/09/14 | 12
CHANGING FOCUS
ON HEALTH CARE
Technology convergence
Pharmacogenomics
3P medicine
Translational medicine
Wireless Health
19. What is a Stent
A small, mesh-like device made of metal
Acts as a support or scaffold, in keeping the vessel open
Stent helps to improve blood flow to the heart muscle and reduce
the pain of angina
80% of patients who have balloon angioplasty will have a stent
placed as well.
20. History
Percutaneous transluminal coronary angioplasty (PTCA) by
Gruntzig in 1977
Puel and Sigwart, in 1986, deployed the first coronary stent to act
as a scaffold
In 2001, drug-eluting stents (DES) were introduced as a strategy
to minimize restenosis
21. Types
Bare metal stents:
Traditional method
May have an increased rate of
re-narrowing due to growth of scar
tissue in the stent, a condition called
Restenosis.
Drug-eluting
stents:
Combat Restenosis
Coated with medications that are slowly released
to block the body's ability to form scar tissue
around the stent. The medication is delivered
directly to the site of the artery blockage.
22. Click to edit Master title style
MEDTECH
“Medical revolution and new technologies”
The challenges
Towards an integrated health system
Our contribution
Innovation: The New Currency of
Competition
11.6.2013 IBM Technology Day 2013, Keynote B. Dubuis 23
25. Access to tools and knowledge
'evolutionary developmental biology'
Electronic health record'
1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 26
26. The shift to patient-empowering, information-leveraging
technologies
“PI” (patient-empowering and information-leveraging) technologies
1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 27
27. Genomic & physiology
Molecular and personalized medicine
Proficient use of Information (e.health)
Access, Cost and Quality of care
1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 29
28. INNOVATION
The New Currency of Competition
1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 30
29. EXPLORE
NEW AVENUES
1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 31
30. WHERE
Towards
HISTORY WRITES
Campus Biotech
1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 32
31. WHERE
ENSURING THAT
HISTORY HISTORY GOES WRITES
ON
1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 33
38. Click to edit Master title style
MEDTECH
“Medical revolution and new technologies”
The challenges
Towards an integrated health system
Our contribution
Anticipate the Future
11.6.2013 IBM Technology Day 2013, Keynote B. Dubuis 40
40. Crossing Visions
19/09/14 | 42
Support the growth
Anticipate the Future
Vitesse moyenne de croissance annuelle 95-00, 00-06
Source: BAK, Basel Economics
41. A Successfull biocluster
Established
access to Capital
Experienced
Business and
Law Firms
Carve-Outs/
Spinouts
Experienced
Entrepreneur Innovation
Initiatives
World-Class
Research
Institutions
World-Class
Business Schools
Experienced
Technical People
IP
Create Value
around IP
PhD’s
MBA’s
Early-Stage
Company
Late-Stage
Emerging/Public
Public
Industry Leader
C://DUBUIS, 2009
1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 43
Charting the shift The accompanying chart shows several existing technologies clustered along two dimensions: whether they are providercontrolled or patient-empowering (on the vertical axis) and the extent to which they are information-leveraging (on the horizontal axis). Historically, the majority of medical technologies have not leveraged information. Some of these products have been targeted at patients (such as contact lenses and hearing aids — shown in Quadrant 2). Other products have been marketed to both patients and physicians (syringes, thermometers, bandages, etc.). But so far, the vast majority of medical technologies have been in Quadrant 1 — products that did not leverage information and were controlled by providers. More and more products are migrating away from Quadrant 1. In some cases, products have started leveraging information even though they are still under the control of providers (e.g., smart beds, which are remaking the lowly hospital bed into a device that can generate and track all sorts of useful health data). In other cases, the initial move was to become more patientempowering even though products still did not leverage information (e.g., traditional blood-pressure cuffs). Over time, however, many of these products will end up squarely in Quadrant 4 — effectively becoming PI technologies. While the blood-pressure monitors that initially moved into patients’ hands may not have been information-leveraging, the most recent iterations certainly are. Indeed, entire classes of diagnostic equipment — from blood-pressure monitors to glucometers and the aforementioned Cardiio heart-rate monitor — are being reinvented in radically patient-friendly ways. Many of these technologies are minimally invasive, compatible with consumer technologies such as smartphones and tablets, and allow patients to track, analyze and learn from their own data. Apnea monitors, for instance, have long been information-leveraging, but they were entirely controlled by providers. Now, sensor-embedded consumer devices such as the Zeo Sleep Manager allow patients to monitor their sleep every day. This gives apnea patients not only ownership over their data, but also more useful data — information that is generated in real-world conditions and provides a longitudinal panel from which to extract true insights into the behaviors and factors that exacerbate one’s ailment. The movement is gaining steam. While many categories of products will likely always remain in hospitals or under the control of physicians, in other categories — diagnostics, monitoring equipment, even some types of imaging products — we are likely to see more and more products empowering patients and leveraging information. The shift is likely to be accelerated not just by the pace of technological innovation, but also by the huge challenges facing health care and the fact that PI technologies can play a critical role in addressing these challenges.